Patent · US Active

Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors

US11202779B2 · kind B2 · utility

0Cited by
2References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 17, 2019
Grant dateDec 21, 2021
Priority date
Expiry dateOct 21, 2039

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.